Elevated serum S100B protein in first-episode drug-naïve Chinese patients with schizophrenia

Schizophrenia Research

Volumn 119, Issue 1-3, 2010, Pages 40-46

  Tan, Yunlong ^a   Luo, Xingguang ^d   Yang, Fude ^a   Zhang, Wufang ^b   Wang, Zhiren ^a   Zou, Yizhuang ^a   Zhang, Xiangyang ^a,c   Wang, Fei ^d   Zuo, Lingjun ^d   Zhou, Dongfeng ^b  

^a BEIJING HUILONGGUAN HOSPITAL   (China)

^b PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chinese; S100B protein; Schizophrenia

Indexed keywords

PROTEIN S100B;

ADULT; AGE DISTRIBUTION; ARTICLE; ASTROCYTE; CHINESE; CONTROLLED STUDY; DISEASE DURATION; DRUG EXPOSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PARANOIA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; SCHIZOPHRENIA; SCORING SYSTEM; UPREGULATION;

EID: 77952668301     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.01.012     Document Type: Article

References (40)

1. American Psychiatric Association, 1994. Diagnostic and Statistical Manual of Mental Disorder.(Fourth ed.) American Psychiatric Association, Washington, DC.
2. Bernstein H.G., Bogerts B., Keilhoff G. The many faces of nitric oxide in schizophrenia. A review. Schizophr. Res. 2005, 78:69-86.
3. De Keyser J., Mostert J.P., Koch M.W. Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders. J. Neurol. Sci. 2008, 267:3-16.
4. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int. J. Biochem. Cell Biol. 2001, 33:637-668.
5. Esposito G., De Filippis D., Cirillo C., Sarnelli G., Cuomo R., Iuvone T. The astroglial-derived S100Beta protein stimulates the expression of nitric oxide synthase in rodent macrophages through p38 MAP kinase activation. Life Sci. 2006, 78:2707-2715.
6. Gattaz W.F., Lara D.R., Elkis H., Portela L.V., Goncalves C.A., Tort A.B., Henna J., Souza D.O. Decreased S100-beta protein in schizophrenia: preliminary evidence. Schizophr. Res. 2000, 43:91-95.
7. Gerlai R., Roder J. Spatial and nonspatial learning in mice: effects of S100 beta overexpression and age. Neurobiol. Learn. Mem. 1996, 66:143-154.
8. Gerlai R., Marks A., Roder J. T-maze spontaneous alternation rate is decreased in S100 beta transgenic mice. Behav. Neurosci. 1994, 108:100-106.
9. Honea R., Crow T.J., Passingham D., Mackay C.E. Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am. J. Psychiatry 2005, 162:2233-2245.
10. Jankovic B.D., Djordjijevic D. Differential appearance of autoantibodies to human brain S100 protein, neuron specific enolase and myelin basic protein in psychiatric patients. Int. J. Neurosci. 1991, 60:119-127.
11. Kochanek P.M., Berger R.P., Bayir H., Wagner A.K., Jenkins L.W., Clark R.S. Biomarkers of primary and evolving damage in traumatic and ischemic brain injury: diagnosis, prognosis, probing mechanisms, and therapeutic decision making. Curr. Opin. Crit. Care 2008, 14:135-141.
12. Kondziella D., Brenner E., Eyjolfsson E.M., Sonnewald U. How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia?. Neurochem. Int. 2007, 50:291-301.
13. Lara D.R., Gama C.S., Belmonte-de-Abreu P., Portela L.V., Goncalves C.A., Fonseca M., Hauck S., Souza D.O. Increased serum S100B protein in schizophrenia: a study in medication-free patients. J. Psychiatr. Res. 2001, 35:11-14.
14. Leite M.C., Galland F., Brolese G., Guerra M.C., Bortolotto J.W., Freitas R., Almeida L.M., Gottfried C., Gonçalves C.A. A simple, sensitive and widely applicable ELISA for S100B: methodological features of the measurement of this glial protein. J. Neurosci. Meth. 2008, 169:93-99.
15. Lieberman J.A. Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia. J. Clin. Psychiatry 1999, 60(Suppl 12):9-12.
16. Ling S.H., Tang Y.L., Jiang F., Wiste A., Guo S.S., Weng Y.Z., Yang T.S. Plasma S-100B protein in Chinese patients with schizophrenia: comparison with healthy controls and effect of antipsychotics treatment. J. Psychiatr. Res. 2007, 41:36-42.
17. Lu, B., Martinowich, K., 2008. Cell Biology of BDNF and Its Relevance to Schizophrenia. Novartis Found Symp 289, 119-129; Discussion 129-135, 193-115.
18. Malaspina D. Schizophrenia: a neurodevelopmental or a neurodegenerative disorder. J. Clin. Psychiatry 2006, 67:e07.
19. McGlashan T.H., Hoffman R.E. Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch. Gen. Psychiatry 2000, 57:637-648.
20. Missler U., Wiesmann M. Measurement of S-100 protein in human blood and cerebrospinal fluid:analytical method and preliminary clinical results. Eur. J. Clin. Chem. Clin. Biochem. 1995, 33:743-748.
21. Miller G. Neuroscience. The dark side of glia. Science 2005, 308:778-781.
22. Muller N., Schwarz M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox Res. 2006, 10:131-148.
23. Nishiyama H., Knopfel T., Endo S., Itohara S. Glial protein S100B modulates long-term neuronal synaptic plasticity. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:4037-4042.
24. Pedersen A., Diedrich M., Kaestner F., Koelkebeck K., Ohrmann P., Ponath G., Kipp F., Abel S., Siegmund A., Suslow T., von Eiff C., Arolt V., Rothermundt M. Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1789-1792.
25. Petzold A., Michel P., Stock M., Schluep M. Glial and axonal body fluid biomarkers are related to infarct volume, severity, and outcome. J. Stroke Cerebrovasc. Dis. 2008, 17:196-203.
26. Portela L.V., Tort A.B., Schaf D.V., Ribeiro L., Nora D.B., Walz R., Rotta L.N., Silva C.T., Busnello J.V., Kapczinski F., Goncalves C.A., Souza D.O. The serum S100B concentration is age dependent. Clin. Chem. 2002, 48:950-952.
27. Powers R.E. The neuropathology of schizophrenia. J. Neuropathol. Exp. Neurol. 1999, 58:679-690.
28. Rothermundt M., Peters M., Prehn J.H., Arolt V. S100B in brain damage and neurodegeneration. Microsc. Res. Tech. 2003, 60:614-632.
29. Rothermundt M., Ponath G., Glaser T., Hetzel G., Arolt V. S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology 2004, 29:1004-1011.
30. Rothermundt M., Missler U., Arolt V., Peters M., Leadbeater J., Wiesmann M., Rudolf S., Wandinger K.P., Kirchner H. Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol. Psychiatry 2001, 6:445-449.
31. Rothermundt M., Falkai P., Ponath G., Abel S., Burkle H., Diedrich M., Hetzel G., Peters M., Siegmund A., Pedersen A., Maier W., Schramm J., Suslow T., Ohrmann P., Arolt V. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol. Psychiatry 2004, 9:897-899.
32. Sarandol A., Kirli S., Akkaya C., Altin A., Demirci M., Sarandol E. Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: effects of short term antipsychotic treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:1164-1169.
33. Schmitt A., Bertsch T., Henning U., Tost H., Klimke A., Henn F.A., Falkai P. Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms. Schizophr. Res. 2005, 80:305-313.
34. Schroeter M.L., Abdul-Khaliq H., Fruhauf S., Hohne R., Schick G., Diefenbacher A., Blasig I.E. Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. Schizophr. Res. 2003, 62:231-236.
35. Schroeter M.L., Abdul-Khaliq H., Krebs M., Diefenbacher A., Blasig I.E. NSE is unaltered whereas S100B is elevated in serum of patients with schizophrenia - original research and meta-analysis. Psych. Res. 2009, 167:66-72.
36. Schulte-Herbruggen O., Hortnagl H., Ponath G., Rothermundt M., Hellweg R. Distinct regulation of brain-derived neurotrophic factor and noradrenaline in S100B knockout mice. Neurosci. Lett. 2008, 442:100-103.
37. Steiner J., Bernstein H.G., Bielau H., Farkas N., Winter J., Dobrowolny H., Brisch R., Gos T., Mawrin C., Myint A.M., Bogerts B. S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: a morphometric study. J. Psychiatr. Res. 2008, 42:868-876.
38. Uranova N.A., Vostrikov V.M., Orlovskaya D.D., Rachmanova V.I. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr. Res. 2004, 67:269-275.
39. Whitaker-Azmitia P.M., Wingate M., Borella A., Gerlai R., Roder J., Azmitia E.C. Transgenic mice overexpressing the neurotrophic factor S-100 beta show neuronal cytoskeletal and behavioral signs of altered aging processes: implications for Alzheimer's disease and Down's syndrome. Brain Res. 1997, 776:51-60.
40. Wiesmann M., Wandinger K.P., Missler U., Eckhoff D., Rothermundt M., Arolt V., Kirchner H. Elevated plasma levels of S-100b protein in schizophrenic patients. Biol. Psychiatry 1999, 45:1508-1511.